Dermatology最新文献

{"title":"Plant Extracts in Rosacea Management: A Narrative Review.","authors":"Mathieu Leti, Lucile Garidou, Stéphane V Cuisiat, Aline Stennevin, Gautier Doat, Fabrice Lestienne","doi":"10.1159/000548793","DOIUrl":"10.1159/000548793","url":null,"abstract":"<p><strong>Background: </strong>Rosacea is a prevalent, chronic inflammatory skin disorder increasingly affecting middle-aged individuals worldwide. Characterized by facial erythema, flushing, papules, pustules, and telangiectasia, rosacea arises from complex, dysregulated immune responses with chronic inflammation and vascular instability. Given its multifactorial nature, treatment approaches focus on managing symptoms and often require a multidisciplinary strategy that integrates targeted skincare, topical and systemic therapies, and physical modalities to address the condition's diverse clinical manifestations, subtypes, and severity effectively. Validated conventional treatments, like metronidazole and azelaic acid, offer symptom relief to varying extents; however, many patients find these therapies insufficient, leading to a growing interest in alternative therapies.</p><p><strong>Summary: </strong>Dermocosmetic products containing natural ingredients, particularly botanicals, are gaining in popularity, driven not only by their reported anti-inflammatory properties and perceived favorable tolerability, but also because they often appear to align with the personal values and beliefs of many individuals, and offer a more holistic approach to care. This review provides an up-to-date summary of advancements in the use of botanical ingredients for the management of rosacea. By exploring both well-studied botanicals and emerging plant extracts, this review highlights the growing role of natural adjunctive treatments in rosacea care.</p><p><strong>Key messages: </strong>Emerging clinical evidence suggests that plant-based ingredients may help alleviate rosacea symptoms by modulating inflammation, regulating keratinization, and supporting vascular health, thereby promoting skin restoration, vessel stability, and reduced sensitivity.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"66-98"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Disease Progression in Hurley I Hidradenitis Suppurativa Patients: A Nested Case-Control Study.","authors":"Andrea Isabel Rodriguez-Sanna, Julia Castro-Martín, Daniel Muñoz-Barba, Alberto Soto-Moreno, Clara Ureña-Paniego, Carmen García-Moronta, Sofía Haselgruber, Francisco Javier León-Pérez, Salvador Arias-Santiago, Alejandro Molina-Leyva","doi":"10.1159/000550322","DOIUrl":"10.1159/000550322","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic, progressive, inflammatory skin disease that leads to structural skin alterations, usually assessed using Hurley stages. In Hurley stage I, the earliest phase, structural changes have not yet occurred. However, disease progression varies among patients; some remain indefinitely in this stage, while others advance to more severe forms. The incidence and factors driving progression remain unclear. The aims of this study were to determine the incidence of Hurley II and III cases in a cohort of Hurley I patients and to explore potential factors and interventions associated with structural progression.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted in Hurley I patients to estimate the cumulative incidence and incidence density of Hurley II-III cases during follow-up. Consecutively, within the cohort of Hurley I patients, a nested case-control study was performed to identify factors associated with structural progression. Patients underwent clinical and ultrasound evaluations. Univariate and multivariate analyses were performed.</p><p><strong>Results: </strong>The study included 133 Hurley I patients evaluated consecutively at the HS unit between January 2017 and March 2024. Mean age was 37.54 (12.87) years, with a female-to-male ratio of 84:49. Regarding progression, cumulative incidence was 50 cases (37.6%) (49 to Hurley II; 1 to Hurley III) and incidence density was 23 cases/100 patients-years. After multivariate analysis, the following variables were significantly and independently associated with progression to Hurley stage: higher number of cigarettes/day (p = 0.009), Hurley Ic stage (p = 0.05), and the increase in abscess count from baseline (categorical) (p = 0.0003). A higher number of abscess drainages (p = 0.047) was associated with a lower risk of progression.</p><p><strong>Conclusion: </strong>These findings suggest that clinical features, smoking habits, and treatment-related variables may help identify those patients more likely to progress. Further studies with larger and more representative cohorts are needed to validate these associations.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"241-251"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of Patients with Cellulitis Stratified by Sex and Age: A Single-Center Study Conducted in Finland.","authors":"Vilma Kantonen, Juulia Kinnunen, Jari Jokelainen, Laura Huilaja, Suvi-Päivikki Sinikumpu","doi":"10.1159/000551360","DOIUrl":"10.1159/000551360","url":null,"abstract":"<p><strong>Introduction: </strong>Few previous studies have examined subgroups of patients with cellulitis for differences in patterns of predisposing factors.</p><p><strong>Methods: </strong>This retrospective study was designed to examine the characteristics and predisposing factors of patients treated for cellulitis at the Oulu University Hospital, Finland, from 2019 to 2023 in subgroups based on sex and age.</p><p><strong>Results: </strong>Of the 907 included patients, 56.8% were male; mean age at diagnosis was 57.5 years and was higher in females than in males (61.2 and 54.7 years, respectively; p < 0.001). A history of cellulitis was reported in 35.5%. Cellulitis was most commonly located in the lower leg (40.8% of patients) and its frequency at this site increased with age (p < 0.001). Systemic symptoms were present at diagnosis in 37.4% patients. Compared with other sites, face cellulitis is less frequently associated with a CRP level >150 mg/L (p < 0.001). Analysis of risk factors found that sores and intravenous drug usage were most common in males, whereas malignancies were more frequent in females. Intravenous drug use was associated with younger age (<49 years), whereas obesity, diabetes, malignancies, and lymphedema were more common in older patients.</p><p><strong>Conclusion: </strong>The findings of this study highlight the need for more focus on the risk factors for cellulitis and on preventing the infection.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"443-448"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Histopathological Predictors of Disease Progression in Stage II Cutaneous Melanoma.","authors":"Luisa Boeti, Laura Del Regno, Lucia Di Nardo, Maria Mannino, Alessandro Di Stefani, Laura Quattrini, Irina Ciobotariu, Marisa Salvi, Ketty Peris","doi":"10.1159/000550996","DOIUrl":"10.1159/000550996","url":null,"abstract":"<p><strong>Introduction: </strong>The recent approval of pembrolizumab and nivolumab for the adjuvant treatment of stage IIB-IIC cutaneous melanoma (CM) significantly improved the relapse-free survival probability of this patient population. Real-life data suggest that not all stage IIB and IIC CM patients will invariably undergo disease progression. There is a growing need for accurate patients' selection for whom adjuvant therapy is expected to be beneficial. The aim of this study was to investigate the baseline clinical and histopathological features associated with tumor recurrence in stage II CM patients in an Italian tertiary referral center.</p><p><strong>Methods: </strong>Patients' clinical features and histopathological tumor characteristics were recorded at the time of melanoma diagnosis. Non-recurrent patients were defined based on a ≥5-year follow-up period; time to disease recurrence was calculated as the time from the diagnosis of the primary tumor until first evidence of melanoma relapse.</p><p><strong>Results: </strong>A total of 103 stage II CM patients, with a median follow-up of 6.2 years, were included. Twenty-one of 103 (20.4%) patients recurred, of whom 15/21 (71.4%) showed disease progression to stage IV disease. Breslow thickness was significantly associated with CM recurrence, with a 70% increased probability of melanoma relapse per each unit increase in Breslow thickness (mm) (OR = 1.7; 95% CI: 1.05-2.7; p = 0.029). Histopathological evidence of ulceration and the mitotic rate did not show a significant association with melanoma progression. Breslow thickness was also associated with a reduced time from melanoma diagnosis to recurrence per each unit increase (mm) (p = 0.032) and with shorter disease-free survival probability (HR: 1.47; 95% CI: 1.05-2.06; p = 0.025).</p><p><strong>Conclusion: </strong>Breslow thickness is a relevant prognostic factor for CM recurrence. Further studies are needed to identify novel prognostic biomarkers.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"435-442"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Pain Management Trends and Barriers to Care in Hidradenitis Suppurativa.","authors":"Leandra A Barnes, Fatuma-Ayaan B Rinderknecht, Lauren A V Orenstein, Haley B Naik","doi":"10.1159/000550402","DOIUrl":"10.1159/000550402","url":null,"abstract":"<p><strong>Introduction: </strong>Pain is the most impactful symptom of hidradenitis suppurativa (HS), and understanding its management practices can guide improvements in care. This study aimed to describe HS pain severity and associated factors, evaluate pain management practices, and identify barriers to pain management.</p><p><strong>Methods: </strong>A cross-sectional survey of self-identified adults with HS was conducted from June 13, 2021 to June 30, 2021. Participants were 18 years or older with a confirmed HS diagnosis by a medical provider or a validated questionnaire. Exposures include demographic, clinical factors.</p><p><strong>Primary outcomes: </strong>quality of life (QoL), assessed using the Skindex Mini (0-18 scale), and pain severity, measured via a numerical rating scale (NRS, 0-10).</p><p><strong>Secondary outcomes: </strong>pain treatments used and barriers to care.</p><p><strong>Results: </strong>A total of 890 eligible respondents resided in 5 countries. 96.9% self-identified as female, 74.0% White, 8.3% Black, 2.6% Asian, 5.3% Hispanic, 1.3% American Indian and Native Alaskan, and 7.1% mixed race. Moderate (NRS 4-6) and severe pain (NRS ≥7) were significantly associated with reduced QoL, with Skindex Mini scores that were higher for moderate (14.6; 95% CI: 14.0, 15.2) and severe pain (16.1; 95% CI: 15.4, 16.7) compared to mild pain on average (NRS ≤3, 10.8; 95% CI: 10.3, 11.3). Younger age, Asian race, difficulty accessing care, and severe disease were independently associated with higher pain (p ≤ 0.002 for all). Reported barriers to pain management included providers not asking about pain, poor provider knowledge, and perceived unwillingness to treat pain. A total of 38.4% of participants reported they had never received a prescription for pain medication. Pain prescriptions were most commonly received from primary care physicians (22.5%) or dermatologists (13.3%), with severe pain linked to increased use of opioids, tramadol, and antiepileptics to treat HS pain (p < 0.05 for all).</p><p><strong>Conclusion: </strong>Pain in HS is linked to lower QoL and barriers to management, emphasizing the need for evidence-based, patient-centered approaches to enhance pain care and address treatment gaps.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"252-263"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13344115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generalized Pustular Psoriasis Confers Increased Risk of Pyoderma Gangrenosum: First Population-Based Evidence.","authors":"Hong Ye, Janmesh D Patel, Arash Pour Mohammad, Carina Shiau, Gordon H Bae","doi":"10.1159/000550044","DOIUrl":"10.1159/000550044","url":null,"abstract":"<p><p><p>Introduction: Generalized pustular psoriasis (GPP) and pyoderma gangrenosum (PG) are rare, severe neutrophilic dermatoses with overlapping autoinflammatory pathways. Although case reports suggest a link between GPP and PG, no population-based studies have quantified this risk.</p><p><strong>Methods: </strong>We performed a retrospective cohort study using the TriNetX federated electronic health record network. Adults (≥18 years) with ICD-10 codes for GPP (L40.1) or non-GPP (L40.0-L40.9 excluding L40.1) from 2018 to 2023 were identified. Controls had no psoriasis diagnosis. Cohorts were 1:1 propensity score matched for age, sex, race, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and rheumatoid arthritis. The primary outcome was new PG diagnosis (L88) post-index. Hazard ratios (HRs) for PG were estimated via matched survival analysis.</p><p><strong>Results: </strong>After matching, the GPP cohort (n = 44,187) had a significantly higher risk of PG than controls (n = 44,187; HR 5.14; 95% CI 2.77-9.53). Non-GPP patients (n = 393,833) also showed elevated PG risk versus controls (n = 393,833; HR 3.83; 95% CI 3.00-4.90). In direct comparison (n = 193,208 each), GPP had greater PG risk than non-GPP (HR 2.33; 95% CI 1.46-3.71). Median follow-up ranged from 687 to 886 days across comparisons.</p><p><strong>Conclusion: </strong>This first population-based evidence demonstrates that GPP confers a markedly increased risk of PG compared to both controls and other psoriasis subtypes. These findings underscore the need for heightened clinical vigilance for PG in GPP patients and may inform targeted surveillance strategies. </p>.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"171-174"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12845517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145741514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Gabapentin Combined with Standard-Dose Antihistamines versus Antihistamine Monotherapy in Prurigo Nodularis: A Prospective Monocentric Real-World Observational Study.","authors":"Duoqin Wang, Taiyu Jin, Lisi Peng, Yanyun Shen, Yiqi Zhu, Zijin Xiao, WenLi Zhang, Shuwen Xu, Yixin Shao, Hui Tang","doi":"10.1159/000551865","DOIUrl":"10.1159/000551865","url":null,"abstract":"<p><strong>Introduction: </strong>Prurigo nodularis (PN), the most common subtype of chronic prurigo, is a chronic pruritic dermatosis. Although gabapentin has been proposed as a second-line treatment for PN, clinical studies assessing its efficacy and safety for PN remain limited. This study evaluated the efficacy and safety of gabapentin in the management of PN and explored an effective and well-tolerated dosing regimen.</p><p><strong>Methods: </strong>In the 12-week prospective real-world observational study, 26 patients with PN were allocated to receive either gabapentin (initial dose 300 mg/day) combined with standard-dose antihistamines (combination group) or standard-dose antihistamine monotherapy (monotherapy group). Dose adjustments of gabapentin were made depending on therapeutic response biweekly, with a maximum of 900 mg daily. Efficacy was assessed using the Peak Pruritus Numerical Rating Scale (PP-NRS), Sleep Disturbance-Numerical Rating Scale, Dermatology Life Quality Index (DLQI), and Hospital Anxiety and Depression Scale (HADS), and Investigator's Global Assessment (IGA) scores. Itching response was defined as a reduction of the PP-NRS scores that is greater than 50% or 4 points compared with baseline.</p><p><strong>Results: </strong>Compared to the monotherapy group (n = 14), the combination group (n = 12) exhibited significantly lower PP-NRS and HADS scores as early as week 2, with a higher proportion of patients showing itching response (75.0% vs. 35.7%). The majority (77.8%) of patients in the combination group reached the itching response at week 12 under 600 mg of gabapentin daily. Adverse effects were mild and resolved following dose reduction.</p><p><strong>Conclusion: </strong>Gabapentin provides faster and superior efficacy in reducing pruritus and anxiety and depression for patients with PN, with a favorable safety profile.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"391-398"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practitioner-Reported Complications in Tattoo Removal.","authors":"Mila Poelhekken, Peter J Velthuis, Esther P M Tjin, Darisa A K Quant, Sebastiaan A S van der Bent","doi":"10.1159/000551910","DOIUrl":"10.1159/000551910","url":null,"abstract":"<p><p><p>Introduction: Q-switched laser treatment is the gold standard for tattoo removal; however, complications such as blistering, scarring, dyspigmentation, infections, and allergic reactions can occur. Potential risk factors include the client's skin type, tattoo age, and ink colour. Moreover, untrained practitioners performing laser tattoo removal and the increasing use of non-evidence-based alternative removal products have raised safety concerns. This study aimed to document practitioner-reported complications in laser tattoo removal, focussing on frequency and associating factors. Secondary objectives were to explore practitioner-reported encounters with alternative removal techniques and treatments performed by untrained practitioners.</p><p><strong>Methods: </strong>A digital survey containing up to 41 questions was distributed among Dutch dermal therapists. The survey addressed treatment protocols, complications of laser tattoo removal, and observations regarding alternative techniques and untrained practitioners in tattoo removal.</p><p><strong>Results: </strong>Of 173 practitioners, 94 (54.3%) actively practiced laser tattoo removal. Complications were reported in an estimated 8.1% of laser tattoo removal treatment sessions, most commonly oedema (3.0%), blistering (1.9%), and haematoma (0.7%). Hypo- and hyperpigmentation were reported in approximately 0.6% of treatments, while hypertrophic scarring and paradoxical darkening were reported in 0.2%. Keloid formation, allergic reactions, ink blow-out, and infection were each reported in 0.1%. Complications were reported more frequently by practitioners treating clients with Fitzpatrick skin types ≥III, coloured tattoos, permanent make-up, previously treated tattoos, and tattoos younger than 1 year. Among practitioners performing laser tattoo removal, 87% reported treating clients previously treated by untrained practitioners, and 81.7% of these practitioners observed complications. Additionally, 31.0% of all practitioners reported clients who had used alternative removal techniques, with complications observed in 56.7%.</p><p><strong>Conclusion: </strong>This is the first study to systematically report practitioner-reported complications in laser tattoo removal. Although laser tattoo removal is generally safe, complications were more frequently reported in the presence of known risk factors. The widespread involvement of untrained practitioners and the use of alternative removal techniques highlight ongoing safety concerns and underscore the need for further research and consideration of regulatory measures. </p>.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"449-456"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13278705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Calcineurin Inhibitors and the Epidermal Barrier in Atopic Dermatitis.","authors":"Joachim W Fluhr, Matthias M Bräutigam, Ehrhardt Proksch","doi":"10.1159/000552559","DOIUrl":"10.1159/000552559","url":null,"abstract":"<p><strong>Background: </strong>The topical calcineurin inhibitors (TCIs) pimecrolimus and tacrolimus offer an effective nonsteroidal option for treating atopic dermatitis (AD), particularly in sensitive skin areas and for long-term use. There are several studies published on the effect of calcineurin inhibitors on the skin barrier, but a comprehensive review on this topic is still missing.</p><p><strong>Summary: </strong>This review summarizes current evidence on the impact of TCIs on epidermal barrier structure and function. Clinical studies in patients with AD show that TCIs improve transepidermal water loss, enhance stratum corneum hydration, and promote normalization of structural proteins such as filaggrin and loricrin. Unlike topical corticosteroids, TCIs do not induce skin atrophy and may even reverse steroid-induced epidermal thinning. Additionally, TCIs partially preserve antimicrobial peptide expression in lesional AD skin, which may help reduce Staphylococcus aureus colonization and support microbial diversity. Positive effects on lipid lamellar organization and natural moisturizing factor levels further support barrier restoration. Animal data suggesting impaired lipid synthesis under TCI treatment contrast with consistent positive findings in clinical studies. Importantly, emerging evidence indicates that TCIs may improve the skin microbiome in AD.</p><p><strong>Key messages: </strong>TCIs exert their beneficial effects on skin inflammation through selective T-cell modulation without disrupting keratinocyte differentiation or dermal matrix components. For this reason, the general indirect positive effects on skin barrier associated with reduction of skin inflammation is not counterbalanced by intrinsic barrier damaging mechanisms as observed with topical steroids. Further studies are needed to evaluate long-term effects on skin structure, microbiome stability, and their integration into biologic treatment algorithms.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"489-500"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiopausin® and Angiopoietin: Unveiling New Mechanisms in Rosacea Treatment through Kinetic Erythema Analysis with the AAREA® Algorithm.","authors":"Rayan Arnaout, Oliver Sorg, Nathalie Satta, Cathy Seilaz, Martine von Englebrechten, Jean-Hilaire Saurat","doi":"10.1159/000547545","DOIUrl":"10.1159/000547545","url":null,"abstract":"<p><strong>Introduction: </strong>Non-transient erythema (NTE) is a major feature of rosacea, but its clinical evaluation is subject to human investigator variability. The angiopoietin-TIE2 receptor tyrosine kinase pathway plays a key role in regulating vascular homeostasis, but was previously overlooked as a target for rosacea therapy. Angiopausin® is a patented plant-based ingredient identified through a molecular phytotherapy screening program as a positive inducer of the angiopoietin-TIE2 pathway, which is the \"gatekeeper of vascular quiescence.\" The objective of this preliminary study was to compare traditional clinical NTE scoring methods with a novel algorithm-assisted approach (AAREA®) aimed at both assessing erythema and exploring the potential scientific interest of analyzing erythema regression patterns in patients with rosacea treated with topical Angiopausin.</p><p><strong>Methods: </strong>Data were obtained from the regular follow-up of patients with mild-to-moderate rosacea, monitored as part of the real-world \"homeostasis in chronic facial dermatosis\" registry cohort. Patients were managed exclusively with Angiopausin (applied twice daily) for up to 64 weeks. Facial redness was evaluated clinically using the global investigator erythema assessment (IEA) score and compared to data generated using the algorithm-assisted approach using an ANOVA with post hoc Tukey tests.</p><p><strong>Results: </strong>Forty-four patients (9 men, 35 women) were included (average follow-up: 29 ± 3 weeks per patient). Reductions in total IEA scores were observed at week 4 (W4; p < 0.05) and through W8 to W64 (p < 0.001). Decreases in individual scores were also observed for flushing, NTE and edema (W4 to W64: p < 0.001), and telangiectasia (W8 to W32; p < 0.001). A high level of agreement (R2 = 0.9566) was observed between the clinical IEA scores and the algorithm-assisted approach. The algorithm-assisted approach also provided quantitative data on redness area and intensity, detected early reductions in NTE, and identified distinctive NTE regression patterns.</p><p><strong>Conclusion: </strong>This study demonstrated the real-world effectiveness of targeting the angiopoietin-TIE2 pathway for managing rosacea, with topical Angiopausin resulting in significant and long-lasting reductions in NTE and other vascular manifestations. It also highlighted how advances in rosacea therapy can be studied by profiling the clinical effects of treatments using artificial intelligence. The AAREA tool provided valuable data for clinical scoring and research into understanding rosacea pathogenesis.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"15-24"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}